AcademicCommunity Cancer Research United
Lenvatinib(Academic and Community Cancer Research United)은 Solid Tumor 표적 ADC로, Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 26.6% (ClinicalTrials.gov NCT04889118). PK: t½ 28 h. 차별점: novel strategy to overcome HCC resistance.
Solid Tumor
Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma
Recruiting
Adenoviral transfection, JC-1, mitochondrial-lysosomal colocalization, and autophagy induc
novel strategy to overcome HCC resistance
targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor
apoptosis and cell cycle arrest in HCC cells
biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma
resistance to systemic therapies limiting outcomes
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
AcademicCommunity Cancer Research United
Lenvatinib(Academic and Community Cancer Research United)은 Solid Tumor 표적 ADC로, Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 26.6% (ClinicalTrials.gov NCT04889118). PK: t½ 28 h. 차별점: novel strategy to overcome HCC resistance.
Solid Tumor
Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma
Recruiting
Adenoviral transfection, JC-1, mitochondrial-lysosomal colocalization, and autophagy induc
novel strategy to overcome HCC resistance
targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor
apoptosis and cell cycle arrest in HCC cells
biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma
resistance to systemic therapies limiting outcomes
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.